We use cookies to make your experience better. To comply with the new e-Privacy directive, we need to ask for your consent to set the cookies.
CEM Corporation launches the Liberty 2.0 line of microwave peptide synthesizers.
(Matthews, North Carolina) April 26, 2022 -
CEM Corporation is
proud to announce the release of its Liberty 2.0 instrumentation line,
the next generation of automated microwave peptide synthesizers. The
Liberty 2.0 series continues to advance CEM’s award-winning SPPS
technology, with developments resulting in enhanced peptide purity,
remarkable synthesis efficiency, and exceptional automation reliability.
The Liberty 2.0 series, like preceding models, utilizes CEM’s High-
Efficiency Solid Phase Peptide Synthesis (HE-SPPS) and CarboMAX
coupling
methodologies, partnering ultra-fast cycle times with high
peptide purity and low solvent usage1. CEM’s recently developed
one-pot coupling/deprotection methodology provides unparalleled
simplicity and efficiency, specifically featured on the Liberty Prime 2.02.
All instrumentation in the Liberty 2.0 line features an innovative
headspace flushing process3 which fosters a cleaner reaction
vessel environment and provides unprecedented levels of peptide purity, even for sequences exceeding 100 amino acids in length.
Enhanced developments in valving and fluidics management have been implemented across the entire Liberty 2.0 line and further
supplement system reliability and performance, particularly under conditions of high-throughput usage. A new digitally-controlled nitrogen
system improves bubbling, draining, and purging, leading to more effective washing and use with green solvent alternatives, such as
N-butylpyrrolidinone (TamiSolve).
The 2.0 series features expanded reagent positions and automation options. Furthermore, all systems incorporate a powerfully updated software package, allowing for advanced programming of complex peptides and post-synthesis modifications. “The Liberty 2.0 series is a significant advancement versus our existing microwave peptide synthesizers. It continues our pursuit of constantly improving peptide synthesis and we believe it will have a significant impact on the market.” says, Jonathan M. Collins, VP Business Development.
Learn more about the Liberty 2.0 line
About CEM
CEM Corporation, a private company based in Matthews, North Carolina, is a leading provider of laboratory instrumentation. The company has subsidiaries in the United Kingdom, Germany, Italy, France, Ireland, Japan, and Singapore, as well as a global network of distributors. CEM designs and manufactures systems for life sciences, analytical laboratories, and processing plants worldwide. The company’s products are used in many industries, including pharmaceutical, biotech, chemical and food processing, as well as academic research.
For more information, contact CEM Corporation
1 US15686719; EP17188963.7
2 US20170226152; WO2017070512
3 Patent Pending
